Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The Product is expected to be the first generic approval on the market
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
New leadership team announced at NATHEALTH Annual General Meeting 2024
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The average time of dilation lasts three to eight hours
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Subscribe To Our Newsletter & Stay Updated